DMAC News and Press, DiaMedica Therapeutics Inc. From 05/15/23

Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision Company Completed a Phase 1C Study in Healthy Volunteers in Australia Affirming Proposed Revised DM199 IV D...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Mon...

2023-04-12 08:19:28 ET TESSCO Technologies  ( TESS ) +87% t echnologies to be acquired for $9.00 per share, valued at ~$161.4M. Altamira Therapeutics  ( CYTO ) +70% . Triton International ( TRTN ) +31% i nfrastructure to buy Triton in $13.3B...

In Conjunction with His Appointment, Mr. Wambeke Purchased $750,000 of Common Shares from DiaMedica in a Private Placement Priced Above Market DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemi...

2023-03-29 10:01:02 ET DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Conference Call March 29, 2023, 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Offi...

2023-03-28 16:32:13 ET DiaMedica Therapeutics press release ( NASDAQ: DMAC ): FY GAAP EPS of -$0.52 in-line. Total cash, cash equivalents and investments of $33.5 million, current liabilities of $2.2 million and working capital of $31.7 million as of December 31, 2022, com...

Conference Call and Webcast March 29 at 8:00 am Eastern Time / 7:00 am Central Time Company has had Ongoing and Successful Communications with the FDA to Address the Clinical Hold Company Completed Part 1 of In-Use Study, Results Support Proposed ReMEDy2 Dose Revision ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33 rd...

DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the app...